All individual trials at Corcept Therapeutics

An AllTrials project

All individual trials at Corcept Therapeutics

4 out of 6

66.7%

$9,660,115

$0

Status	Sponsor	Trial ID	Title	Completion date	Days overdue
reported	Corcept Therapeutics	NCT02804750	Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome [pACT]	2018-09-30
reported-late	Corcept Therapeutics	NCT02762981	Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors [pACT]	2020-05-12	442
reported-late	Corcept Therapeutics	NCT03823703	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)	2021-04-05	92
reported-late	Corcept Therapeutics	NCT04329949	A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)	2021-08-23	380
overdue	Corcept Therapeutics	NCT03818256	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia or Bipolar Disorder and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)	2022-12-31	40
overdue	Corcept Therapeutics	NCT03437941	Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer	2023-01-09	31
ongoing	Corcept Therapeutics	NCT04524403	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia Taking Antipsychotic Medications (GRATITUDE II)	2023-01-31
ongoing	Corcept Therapeutics	NCT03776812	A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	2023-03-31
ongoing	Corcept Therapeutics	NCT04308590	Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant	2023-10-31
ongoing	Corcept Therapeutics	NCT05772169	Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)	2024-01-31
ongoing	Corcept Therapeutics	NCT03697109	Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant	2024-03-31
ongoing	Corcept Therapeutics	NCT05407324	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS)	2024-05-31
ongoing	Corcept Therapeutics	NCT05257408	A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)	2024-06-30
ongoing	Corcept Therapeutics	NCT03604198	An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome	2024-12-31
ongoing	Corcept Therapeutics	NCT06108219	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis (MONARCH)	2025-12-31

Download this data